Radhika Bansal, MD, discusses the feasibility and safety of administering axicabtagene ciloleucel (Yescarta) and brexucabtagene autoleucel (Tecartus) in the outpatient setting in patients with relapsed/refractory non-Hodgkin lymphoma.
library.ehaweb.org/eha/2024/e...
The HealthTree Foundation brings information from the experts to the patients! Learn more at healthtree.org/
Donate to the HealthTree Foundation or learn more about additional blood cancer support we offer here: give.healthtree.org/campaign/...
HealthTree Cure Hub helps you find your best treatment options and accelerate cure for blood cancers. Join today at www.healthtree.org/
20 июн 2024
